PTGX Q3 2023 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$38M

Net Income

-$34M

EPS (Diluted)

$-0.58

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$330M

Total Liabilities

$28M

Stockholders' Equity

$302M

Cash & Equivalents

$231M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$38M	-$32M	-18.6%
Net Income	-$34M	-$31M	-9.2%